+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07692529

Exploring the Effectiveness and Safety of Zeprumetostat in Treating Relapsed or Refractory Large Granular Lymphocyte Leukemia

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-11-04

10

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring the effects and safety of zeprumetostat in patients with relapsed or refractory large granular T-cell leukemia. This single-arm, early-phase clinical trial plans to enroll 10 patients who have this rare blood cancer and have not responded well to previous treatments. The purpose is to understand how well zeprumetostat works and how safe it is for these patients. Participants will first go through up to a 4-week screening period before starting treatment. They will then receive oral zeprumetostat at a dose of 350 mg twice daily for 28 days, which counts as one treatment cycle. The treatment phase lasts for two cycles 8 weeks total. If side effects occur, the treatment may be paused and restarted following specific guidelines. During the study, participants will be closely monitored for how many achieve hematological remission after two treatment cycles. Researchers will also track side effects, time to partial or complete remission, quality of life changes, and how long benefits last before disease recurrence. The study includes regular assessments and aims to understand both the treatments impact and safety over at least eight weeks, with some follow-up planned for up to two years.

CONDITIONS

Brief Title

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here